|
End-of-day quote
Egyptian Exchange
2026-08-30
|
5-day change | 1st Jan Change | ||
| 413.02 EGP | -7.19% |
|
-15.25% | +548.89% |
| 08-13 | GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 05-17 | GlaxoSmithKline Q1 consol net profit EGP 4.7 million | RE |
Chart: Technical Analysis
Stock exchange
Egyptian Exchange
BIOC 413.02 £
-7.19%
130M
£
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
Egyptian Exchange
| BIOC | 413.02EGP | -7.19% | 130M £ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 550 | 550 | 521.01 |
| Spread/Res. | -24.91% | -24.91% | -20.73% |
| Spread/Supp. | +67.38% | +129.98% | +137.53% |
| Support | 246.75 | 179.59 | 173.88 |
- Stock Market
- Stocks
- BIOC Stock
- Charts GlaxoSmithKline S.A.E
Select your edition
All financial news and data tailored to specific country editions
